06:20 AM EDT, 10/13/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We revised our target price to USD98 (up from USD86), which implies 19.3x our 2026 EPADS estimate, largely in line with its five-year historical forward P/E. On October 10, U.S. President Trump announced an agreement with AZN to lower the cost of medicines in the U.S, marking the second such agreement between the U.S. government and a pharmaceutical company following Pfizer's deal on September 30. Under the agreement, AZN will offer direct-to-consumer sales to eligible patients with prescriptions for chronic diseases at a discount of up to 80% off list prices, and will participate in the TrumpRx.gov direct purchasing platform. AZN also reached an agreement to delay Section 232 tariffs for three years, allowing the company time to fully onshore its manufacturing operations so that all medicines sold in the U.S. are produced in the country. While pricing pressure remains, we view the announcement positively as it provides some clarity after months of uncertainty for the sector.